EAT is up +49.38%% since April’24 pick View All Top Buy Picks
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of GNFT.PA
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Genfit SA stock price ended at 3.65€ on Wednesday, after losing 0.410%.
(Updated on Jun 26, 2024)

Sell candidate since Jun 14, 2024 Loss -9.10% PDF

The Genfit SA stock price fell by -0.410% on the last day (Wednesday, 26th Jun 2024) from 3.66€ to 3.65€. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 6.96% from a day low at 3.59€ to a day high of 3.84€. The price has fallen in 8 of the last 10 days and is down by -21.78% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -104 thousand shares and in total, 211 thousand shares were bought and sold for approximately 768.42€ thousand.

Given the current short-term trend, the stock is expected to rise 33.35% during the next 3 months and, with a 90% probability hold a price between 4.86€ and 7.80€ at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

GNFT.PA Signals & Forecast

There are few to no technical positive signals at the moment. The Genfit SA stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at 3.76€ and 4.14€. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, May 30, 2024, and so far it has fallen -32.50%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for Genfit SA stock

Genfit SA finds support from accumulated volume at 3.47€ and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved 0.250€ between high and low, or 6.96%. For the last week the stock has had daily average volatility of 6.20%.

Genfit SA is oversold on RSI14 (13). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (GNFT.PA) For The Upcoming Trading Day Of Thursday 27th

For the upcoming trading day on Thursday, 27th we expect Genfit SA to open at 3.69€, and during the day (based on 14 day Average True Range), to move between 3.31€ and 3.98€, which gives a possible trading interval of +/-0.330€ (+/-9.06%) up or down from last closing price. If Genfit SA takes out the full calculated possible swing range there will be an estimated 18.13% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at 3.47€ (4.94%) than the resistance at 3.92€ (7.41%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Genfit SA stock A Buy?

The Genfit SA stock holds several negative signals and despite the positive trend, we believe Genfit SA will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.995 Sell Candidate Unchanged

Predicted Opening Price for Genfit SA of Thursday, June 27, 2024

Fair opening price June 27, 2024 Current price
3.69€ ( 1.28%) 3.65€

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for GNFT.PA

Fibonacci Support & Resistance Levels

Level Price
R3 3.94 8.14%
R2 3.85 5.52%
R1 3.79 3.90%
Price 3.65
S1 3.60 -1.34%
S2 3.54 -2.96%
S3 3.44 -5.58%

Accumulated Volume Support & Resistance Levels

Level Price
R3 4.15 13.85%
R2 4.01 10.01%
R1 3.92 7.41%
Price 3.65
S1 3.47 -4.94%
S2 3.22 -11.66%
S3 3.20 -12.21%

FAQ

What is the symbol for Genfit SA Stock and on which exchange is it traded?
The symbol for Genfit SA is GNFT.PA and it is traded on the PAR (Euronext Paris).

Should I buy or sell Genfit SA Stock?
The Genfit SA stock holds several negative signals and despite the positive trend, we believe Genfit SA will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Genfit SA Stock?
Genfit SA Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Genfit SA Stock.

What's the current price of Genfit SA Stock?
As of the end of day on the Jun 26, 2024, the price of an Genfit SA (GNFT.PA) share was 3.65€.

What is the 52-week high and low for Genfit SA Stock?
The 52-week high for Genfit SA Stock is 5.79€ and the 52-week low is 2.84€.

What is the market capitalization of Genfit SA Stock?
As of the Jun 26, 2024, the market capitalization of Genfit SA is 181.21M.

When is the next earnings date for Genfit SA?
The upcoming earnings date for Genfit SA is Sep 19, 2024.
Click to get the best stock tips daily for free!

About Genfit SA

Genfit SA Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat ... GNFT.PA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT